Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors

This study is testing a medication called avapritinib to see if it can stop the growth of certain types of solid tumors. It is designed for patients whose cancer has specific genetic changes known as CKIT or PDGFRA mutations.

This trial is for adults (and some teenagers 12+) with advanced solid tumors that have not responded to or are not helped by standard treatments. You must have a specific genetic mutation, and you cannot have a gastrointestinal stromal tumor (GIST).

Participants will receive avapritinib, which is a targeted therapy designed to block the proteins that help cancer cells grow. Throughout the study, doctors will monitor how your body reacts to the medicine and how your tumor responds.

The study is currently recruiting new participants and is taking place in Houston, Texas. You will need to discuss the specific time commitment and visit schedule with the research team.